# US 2022/0031682 A1 · Sphingosine kinase 2 inhibitor for treating coronavirus infection > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2022/0031682 A1 - Document ID: US20220031682A1 - Status: Published application - Kind: A1 - Application number: 17/502,932 - Filed: 2021-10-15 - Published: 2022-02-03 - Earliest claimed: 2020-03-10 - Assignees: RedHill Biopharma Ltd. - Applicants: RedHill Biopharma Ltd. - Inventors: Dror Ben-Asher; Reza Fathi - Web page: https://patentgrep.com/patent/US20220031682A1 ## CPC - A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)} - A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid - A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) - A61P 31/14: for RNA viruses - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection. ## Claims ### Claim 1 A method for the treatment of the 2019 coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus, comprising administering to a patient with moderate to severe COVID-19-related pneumonia an effective amount of ABC294640, as a free base or salt thereof. ### Claim 2 (depends on 1) The method of claim 1, wherein the ABC294640 is in the form of its hydrochloride salt. ### Claim 3 (depends on 2) The method of claim 2, further comprising a pharmaceutically-acceptable carrier material, wherein the ABC294640 hydrochloride and the pharmaceutically-acceptable carrier material are in a unit dosage form suitable for oral administration. ### Claim 4 (depends on 3) The method of claim 3, wherein the unit dosage form is a solid dosage form. ### Claim 5 (depends on 4) The method of claim 4, wherein the solid dosage form is a capsule. ### Claim 6 (depends on 1) The method of claim 1, wherein the patient with moderate to severe COVID-19-related pneumonia has hypoxia and is on supplemental oxygen. ### Claim 7 (depends on 1) The method of claim 1, wherein the patient with moderate to severe COVID-19-related pneumonia is a hospitalized patient. ### Claim 8 (depends on 7) The method of claim 7, wherein the hospitalized patient does not require mechanical ventilation. ### Claim 9 (depends on 7) The method of claim 7, wherein the hospitalized patient is on supplemental oxygen. ### Claim 10 (depends on 7) The method of claim 7, wherein the hospitalized patient is receiving oxygen via nasal cannula. ### Claim 11 (depends on 1) The method of claim 1, wherein the SARS-CoV-2 virus is wild-type. ### Claim 12 (depends on 1) The method of claim 1, wherein the SARS-CoV-2 virus is a naturally occurring coronavirus variant. ### Claim 13 (depends on 3) The method of claim 3, wherein the unit dosage form suitable for oral administration is a capsule having 250 mg of ABC294640 hydrochloride, and wherein administering includes two capsules administered twice a day, for at least 10 days, for a total daily dose of 1000 mg of ABC294640 hydrochloride. ### Claim 14 (depends on 2) The method of claim 2 comprising ABC294640 hydrochloride and a pharmaceutically-acceptable carrier material, wherein the pharmaceutically-acceptable carrier material is physiologically buffered saline. ### Claim 15 (depends on 14) The method of claim 14, wherein a suspension is formed that includes ABC294640 hydrochloride suspended in physiologically buffered saline, and wherein the administering includes using a tube to deliver the suspension directly to the stomach. ### Claim 16 A method of treatment comprising administering an effective amount of ABC294640, as a free base or salt thereof, to a patient with moderate to severe COVID-19-related pneumonia caused by the SARS-CoV-2 virus. ### Claim 17 (depends on 16) The method of claim 16, wherein the ABC294640 is in the form of its hydrochloride salt. ### Claim 18 (depends on 17) The method of claim 17, further comprising a pharmaceutically-acceptable carrier material, wherein the ABC294640 hydrochloride and the pharmaceutically-acceptable carrier material are in a unit dosage form suitable for oral administration. ### Claim 19 (depends on 18) The method of claim 18, wherein the unit dosage form is a solid dosage form. ### Claim 20 (depends on 19) The method of claim 19, wherein the solid dosage form is a capsule. ### Claim 21 (depends on 16) The method of claim 16, wherein the patient with moderate to severe COVID-19-related pneumonia has hypoxia and is on supplemental oxygen. ### Claim 22 (depends on 16) The method of claim 16, wherein the patient with moderate to severe COVID-19-related pneumonia is a hospitalized patient. ### Claim 23 (depends on 22) The method of claim 22, wherein the hospitalized patient does not require mechanical ventilation. ### Claim 24 (depends on 22) The method of claim 22, wherein the hospitalized patient is on supplemental oxygen. ### Claim 25 (depends on 22) The method of claim 22, wherein the hospitalized patient is receiving oxygen via nasal cannula. ### Claim 26 (depends on 16) The method of claim 16, wherein the SARS-CoV-2 virus is wild-type. ### Claim 27 (depends on 16) The method of claim 16, wherein the SARS-CoV-2 virus is a naturally occurring coronavirus variant. ### Claim 28 (depends on 18) The method of claim 18, wherein the unit dosage form suitable for oral administration is a capsule having 250 mg of ABC294640 hydrochloride, and wherein administering includes two capsules administered twice a day, for at least 10 days, for a total daily dose of 1000 mg of ABC294640 hydrochloride. ### Claim 29 (depends on 17) The method of claim 17 comprising ABC294640 hydrochloride and a pharmaceutically-acceptable carrier material, wherein the pharmaceutically-acceptable carrier material is physiologically buffered saline. ### Claim 30 (depends on 29) The method of claim 29, wherein a suspension is formed that includes ABC294640 hydrochloride suspended in physiologically buffered saline, and wherein the administering includes using a tube to deliver the suspension directly to the stomach.